Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.86 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 10/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13942147 | 1.00 | METTL3 (0.86) | METTL3GAAEGFRMAPTTP53 | |
| SCHEMBL19829420 | 0.94 | METTL3 (0.88) | METTL3GAAEGFRMAPTPLA2G4A | |
| SCHEMBL1104875 | 0.94 | METTL3 (0.88) | METTL3GAAEGFRMAPTPLA2G4A | |
| SCHEMBL21104379 | 0.93 | METTL3 (0.82) | METTL3GAAEGFRMAPTTP53 | |
| SCHEMBL1104899 | 0.93 | METTL3 (0.82) | METTL3GAAEGFRMAPTTP53 | |
| SCHEMBL4360879 | 0.93 | METTL3 (0.82) | METTL3GAAEGFRMAPTTP53 | |
| Elvitegravir SCHEMBL13225651 | 0.93 | METTL3 (1.00) | METTL3GAAEGFRMAPTTP53 | |
| Elvitegravir SCHEMBL726251 | 0.93 | METTL3 (1.00) | METTL3GAAEGFRMAPTTP53 | |
| Elvitegravir SCHEMBL726252 | 0.93 | METTL3 (1.00) | METTL3GAAEGFRMAPTTP53 | |
| Elvitegravir SCHEMBL29623981 | 0.93 | METTL3 (1.00) | METTL3GAAEGFRMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-2906540-B1 | AN IMPROVED PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | ZENTIVA KS (CZ) | 2018-07-04 | — | — | EP | disclosed |
| US-20090233964-A1 | METHODS FOR IMPROVING THE PHARMACOKINETICS OF HIV INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233964-A1 | METHODS FOR IMPROVING THE PHARMACOKINETICS OF HIV INTEGRASE INHIBITORS | APOBEC3C, TMPRSS15, APOBEC3G | METTL3 2482/4885GAA 249/4885EGFR 3430/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | METTL3 1258/4885GAA 331/4885EGFR 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.